RESPONSE TO THALIDOMIDE AND CYCLOSPORINE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME WITHOUT ISOLATED DEL(5Q)

被引：1
|
作者：
Wang, J. [1 ]
Qin, T. [1 ]
Xu, Z. [1 ]
Zhang, Y. [1 ]
Gale, R. [2 ]
Fang, L. [1 ]
Zhang, H. [1 ]
Pan, L. [1 ]
Hu, N. [1 ]
Qu, S. [1 ]
Li, B. [1 ]
Xiao, Z. [1 ]
机构：
[1] Inst Hematol & Blood Dis Hosp, MDS & MPN Ctr, Tianjin, Peoples R China
[2] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30256-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
255
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [1] Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
    Hong, Junshik
    Lee, Yoo Jin
    Bae, Sung Hwa
    Yi, Jun Ho
    Park, Sungwoo
    Chang, Myung Hee
    Park, Young Hoon
    Hyun, Shin Young
    Chung, Joo-Seop
    Jang, Ji Eun
    Jung, Joo Young
    Jeon, So-Yeon
    Song, Seo-Young
    Kim, Hawk
    Kim, Dae Sik
    Kim, Sung-Hyun
    Kim, Min Kyoung
    Han, Sang Hoon
    Park, Seonyang
    Kim, Yoo-Jin
    Lee, Je-Hwan
    BLOOD RESEARCH, 2021, 56 (02) : 102 - 107
  • [2] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan F.
    Selleslag, Dominik
    Mittelman, Moshe
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Li, Jack Shiansong
    Sugrue, Mary M.
    Fenaux, Pierre
    BLOOD CANCER JOURNAL, 2018, 8
  • [3] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Mikkael A. Sekeres
    Arlene S. Swern
    Aristoteles Giagounidis
    Alan F. List
    Dominik Selleslag
    Moshe Mittelman
    Brigitte Schlegelberger
    Gudrun Göhring
    Jack Shiansong Li
    Mary M. Sugrue
    Pierre Fenaux
    Blood Cancer Journal, 8
  • [4] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    Sekeres, M. A.
    Swern, A. S.
    Fenaux, P.
    Greenberg, P. L.
    Sanz, G. F.
    Bennett, J. M.
    Dreyfus, F.
    List, A. F.
    Li, J. S.
    Sugrue, M. M.
    BLOOD CANCER JOURNAL, 2014, 4 : e242 - e242
  • [5] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    M A Sekeres
    A S Swern
    P Fenaux
    P L Greenberg
    G F Sanz
    J M Bennett
    F Dreyfus
    A F List
    J S Li
    M M Sugrue
    Blood Cancer Journal, 2014, 4 : e242 - e242
  • [6] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Valeria Santini
    Pierre Fenaux
    Aristoteles Giagounidis
    Uwe Platzbecker
    Alan F. List
    Torsten Haferlach
    Jim Zhong
    Chengqing Wu
    Konstantinos Mavrommatis
    C. L. Beach
    Kyle J. MacBeth
    Antonio Almeida
    Leukemia, 2021, 35 : 897 - 900
  • [7] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Haferlach, Torsten
    Zhong, Jim
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    MacBeth, Kyle J.
    Almeida, Antonio
    LEUKEMIA, 2021, 35 (03) : 897 - 900
  • [8] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Butrym, Aleksandra
    Lech-Maranda, Ewa
    Patkowska, Elzbieta
    Kumiega, Beata
    Bieniaszewska, Maria
    Mital, Andrzej
    Madry, Krzysztof
    Torosian, Tigran
    Wichary, Ryszard
    Rybka, Justyna
    Warzocha, Krzysztof
    Mazur, Grzegorz
    BMC CANCER, 2015, 15
  • [9] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    BMC Cancer, 15
  • [10] Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
    Almeida, Antonio
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Goldberg, Stuart L.
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2135 - 2143
12345